Environmentally responsive dual-targeting nanotheranostics for overcoming cancer multidrug resistance

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Cancer Therapy

Background:

• Multiple drug resistance (MDR) limits chemotherapy effectiveness, posing a significant challenge in cancer treatment.
• P-glycoprotein (P-gp) overexpression is a key mechanism driving MDR in various cancers.
• Targeted delivery systems are crucial for enhancing therapeutic specificity and overcoming drug resistance.

Purpose of the Study:

• To develop a novel nanotheranostic system for overcoming MDR by inhibiting P-gp.
• To co-deliver the anticancer drug doxorubicin, the P-gp inhibitor XMD8-92, and superparamagnetic iron oxide nanoparticles (SPIOs).
• To evaluate the efficacy and safety of the developed nanotheranostics in MDR cancer models.

Main Methods:

• Fabrication of a poly(ethylene glycol)-blocked-poly(L-leucine) (PEG-b-Leu) micelle system encapsulating doxorubicin, XMD8-92, and SPIOs (DXS@NPs).
• In vitro assessment of cytotoxicity on MDR cancer cells (SCG 7901/VCR).
• In vivo evaluation of tumor inhibition and systemic toxicity in MDR tumor-bearing mice.

Main Results:

• The DXS@NPs demonstrated significant in vitro cytotoxicity against MDR cells, with only 53% cell survival compared to 90% for doxorubicin alone.
• The nanotheranostics exhibited efficient tumor inhibition in vivo.
• Treatment with DXS@NPs resulted in substantially reduced systemic toxicity.

Conclusions:

• The developed environmentally responsive, dual-targeting nanotheranostics (DXS@NPs) show great promise for overcoming cancer MDR.
• This approach offers controllable drug delivery and effective MR imaging capabilities.
• DXS@NPs represent a potential breakthrough strategy for enhancing cancer chemotherapy efficacy in drug-resistant cases.